Topic: non-small cell lung cancer
Chloroquine fails in China study, as India bans its export. China halts BeiGene's Abraxane supply. MET inhibitor Tepmetko wins first global nod.
An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.
The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.
Because of the China COVID-19 epidemic, AstraZeneca pared its 2020 revenue forecast—and at a time when three key cancer meds missed their marks.
Novartis has secured FDA priority review for MET inhibitor capmatinib, which could compete with Merck KGaA's tepotinib.
BMS said the decision came after EU drug reviewers found it difficult to assess phase 3 trial data because of multiple protocol changes.
Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.
It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.
Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.
BMS has been waiting years to get a crack at the previously untreated NSCLC market, but the end to its waiting may finally be in sight.